DE69018799D1 - IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie. - Google Patents

IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.

Info

Publication number
DE69018799D1
DE69018799D1 DE69018799T DE69018799T DE69018799D1 DE 69018799 D1 DE69018799 D1 DE 69018799D1 DE 69018799 T DE69018799 T DE 69018799T DE 69018799 T DE69018799 T DE 69018799T DE 69018799 D1 DE69018799 D1 DE 69018799D1
Authority
DE
Germany
Prior art keywords
igf
treatment
side effects
steroid therapy
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018799T
Other languages
English (en)
Other versions
DE69018799T2 (de
Inventor
Ronald L Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of DE69018799D1 publication Critical patent/DE69018799D1/de
Publication of DE69018799T2 publication Critical patent/DE69018799T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69018799T 1989-12-22 1990-12-13 IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie. Expired - Fee Related DE69018799T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45521589A 1989-12-22 1989-12-22

Publications (2)

Publication Number Publication Date
DE69018799D1 true DE69018799D1 (de) 1995-05-24
DE69018799T2 DE69018799T2 (de) 1995-09-21

Family

ID=23807878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018799T Expired - Fee Related DE69018799T2 (de) 1989-12-22 1990-12-13 IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.

Country Status (14)

Country Link
EP (1) EP0434625B1 (de)
JP (1) JP2934023B2 (de)
KR (1) KR100191381B1 (de)
AT (1) ATE121296T1 (de)
AU (1) AU641966B2 (de)
CA (1) CA2032859C (de)
DE (1) DE69018799T2 (de)
DK (1) DK0434625T3 (de)
ES (1) ES2071080T3 (de)
GR (1) GR3015900T3 (de)
IE (1) IE67510B1 (de)
IL (1) IL96711A (de)
NZ (1) NZ236614A (de)
ZA (1) ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
EP0779927A1 (de) * 1994-09-08 1997-06-25 Chiron Corporation Methode zur gesteigerten herstellung von insulin-ähnlichem wachstumsfaktor
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1997015319A1 (en) * 1995-10-23 1997-05-01 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
JP2002510646A (ja) 1998-04-03 2002-04-09 カイロン コーポレイション 関節軟骨障害を処置するためのigfiの使用
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
EP1917039A4 (de) * 2005-08-01 2011-01-19 Genera Istrazivanja D O O Verfahren und zusammensetzungen zur regeneration von gelenkknorpel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289584B1 (de) * 1986-11-14 1993-05-05 Institute of Molecular Biology, Inc. Wundheilung und knochenregeneration
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β

Also Published As

Publication number Publication date
EP0434625A3 (en) 1991-10-02
AU6824790A (en) 1991-06-27
NZ236614A (en) 1993-10-26
GR3015900T3 (en) 1995-07-31
CA2032859A1 (en) 1991-06-23
IL96711A (en) 1996-01-19
ES2071080T3 (es) 1995-06-16
KR100191381B1 (ko) 1999-06-15
AU641966B2 (en) 1993-10-07
CA2032859C (en) 2007-09-17
IE67510B1 (en) 1996-04-03
JPH04210648A (ja) 1992-07-31
IE904684A1 (en) 1991-07-17
DE69018799T2 (de) 1995-09-21
JP2934023B2 (ja) 1999-08-16
DK0434625T3 (da) 1995-06-26
ATE121296T1 (de) 1995-05-15
IL96711A0 (en) 1991-09-16
KR910011279A (ko) 1991-08-07
EP0434625B1 (de) 1995-04-19
EP0434625A2 (de) 1991-06-26
ZA9010332B (en) 1991-08-28

Similar Documents

Publication Publication Date Title
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69016768T2 (de) Zusammensetzung und Verfahren für die Behandlung von Osteoporose bei Säugetieren.
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
ATE186840T1 (de) Zusammensetzungen und methoden zur wundbehandlung
ES2113857T3 (es) Composiciones osteoinductoras.
DE69528058D1 (de) Bmp-9 zusammensetzungen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee